1. Neurological Disease

Neurological Disease

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-14953R
    Imepitoin (Standard) 188116-07-6 98%
    Imepitoin (Standard) is the analytical standard of Imepitoin. This product is intended for research and analytical applications. Imepitoin (AWD 131-138) is a new low-affinity partial benzodiazepine receptor agonist with potent anticonvulsant and anxiolytic properties in rodent models.
    Imepitoin (Standard)
  • HY-149703
    M1/M4 muscarinic agonist 2 98%
    M1/M4 muscarinic antagonist 2 (compound 40) is a selective M1 and M4 agonist with IC5019 nM and 42 nM, respectively.
    M1/M4 muscarinic agonist 2
  • HY-150179
    ALCAT1-IN-1 2245767-05-7 98%
    ALCAT1-IN-1 is an ALCAT1 inhibitor.ALCAT1-IN-1 can be used for the research of aging and age-related diseases.
    ALCAT1-IN-1
  • HY-150333
    MMB-ICA 1188516-52-0 98%
    MMB-ICA is a metabolite of MMB-CHMICA.
    MMB-ICA
  • HY-150334
    Rilmazolam 50330-59-1 98%
    Rilmazolam is a metabolite of Rilmazafone (HY-106547) and hypnotic agent. Rilmazolam exerts a significant sleep-inducing effect. Rilmazolam can be used in insomnia-related research.
    Rilmazolam
  • HY-150335
    Dehydrocannabifuran 56154-59-7 98%
    Dehydrocannabifuran (6-Methyl-9-isopropenyl-3-pentyldibenzofuran-1-ol) is a phytocannabinoid derivative.
    Dehydrocannabifuran
  • HY-150339
    AB-INACA 1887742-41-7 98%
    AB-INACA is a metabolite of AB-CHMINACA.
    AB-INACA
  • HY-150340
    N-Butyl Pentedrone hydrochloride 18268-13-8 98%
    N-Butyl Pentedrone hydrochloride is a drug derivative.
    N-Butyl Pentedrone hydrochloride
  • HY-150341
    Ortho-methyl 4-anilino-1-boc-piperidine 1154101-90-2 98%
    Ortho-methyl 4-anilino-1-boc-piperidine is a precursor in the synthesis of a compound.
    Ortho-methyl 4-anilino-1-boc-piperidine
  • HY-150342
    1-Propinoyl Lysergic acid methylisopropylamide 3028950-73-1 98%
    1-Propinoyl Lysergic acid methylisopropylamide (1P-MiPLA) is a lysergamide compound.
    1-Propinoyl Lysergic acid methylisopropylamide
  • HY-150343
    (±)-3-Methyl nimetazepam 89141-65-1 98%
    (±)-3-Methyl nimetazepam is a benzodiazepine.
    (±)-3-Methyl nimetazepam
  • HY-150344
    Abnormal cannabidivarin 55824-20-9 98%
    Abnormal cannabidivarin (Abn-Cannabidivarin) is a byproduct in the synthesis of Cannabidivarin.
    Abnormal cannabidivarin
  • HY-150345
    Δ8-THC Glucuronide 62667-60-1 98%
    Δ8-THC Glucuronide is a phytocannabinoid metabolite.
    Δ8-THC Glucuronide
  • HY-150346
    1cP-MiPLA 3028950-74-2 98%
    1cP-MiPLA is a lysergamide.
    1cP-MiPLA
  • HY-150347
    Cannabigerol diacetate 1040411-87-7 98%
    Cannabigerol diacetate is structurally similar to known phytocannabinoids.
    Cannabigerol diacetate
  • HY-150348
    Cannabidivarin diacetate 2552800-24-3 98%
    Cannabidivarin diacetateis structurally similar to known phytocannabinoids.
    Cannabidivarin diacetate
  • HY-150349
    (±)-3-Methyl nitrazepam 4928-07-8 98%
    (±)-3-Methyl nitrazepam is a benzodiazepine.
    (±)-3-Methyl nitrazepam
  • HY-15064R
    HC-030031 (Standard) 349085-38-7 98%
    HC-030031 (Standard) is the analytical standard of HC-030031. This product is intended for research and analytical applications. HC-030031 is a potent and selective TRPA1 inhibitor, which antagonizes AITC- and formalin-evoked calcium influx with IC50s of 6.2±0.2 and 5.3±0.2 μM, respectively.
    HC-030031 (Standard)
  • HY-15066R
    CNQX (Standard) 115066-14-3 98%
    CNQX (Standard) is the analytical standard of CNQX. This product is intended for research and analytical applications. CNQX (FG9065) is a potent and competitive AMPA/kainate receptor antagonist with IC50s of 0.3 μM and 1.5 μM, respectively. CNQX is a competitive non-NMDA receptor antagonist. CNQX blocks the expression of fear-potentiated startle in rats.
    CNQX (Standard)
  • HY-15068R
    NBQX (Standard) 118876-58-7 98%
    NBQX (Standard) is the analytical standard of NBQX. This product is intended for research and analytical applications. NBQX (FG9202) is a highly selective and competitive AMPA receptor antagonist. NBQX has neuroprotective and anticonvulsant activity.
    NBQX (Standard)
Cat. No. Product Name / Synonyms Application Reactivity